Streptomyces rochei MS-37 as a Novel Marine Actinobacterium for Green Biosynthesis of Silver Nanoparticles and Their Biomedical Applications

Abstract

Periodontitis, as one of the most common diseases on a global scale, is a public health concern. Microbial resistance to currently available antimicrobial agents is becoming a growing issue in periodontal treatment. As a result, it is critical to develop effective and environmentally friendly biomedical approaches to overcome such challenges. The investigation of Streptomyces rochei MS-37’s performance may be the first of its kind as a novel marine actinobacterium for the green biosynthesis of silver nanoparticles (SNPs) and potentials as antibacterial, anti-inflammatory, antibiofilm, and antioxidant candidates suppressing membrane-associated dental infections. Streptomyces rochei MS-37, a new marine actinobacterial strain, was used in this study for the biosynthesis of silver nanoparticles for various biomedical applications. Surface plasmon resonance spectroscopy showed a peak at 429 nm for the SNPs. The SNPs were spherical, tiny (average 23.2 nm by TEM, 59.4 nm by DLS), very stable (−26 mV), and contained capping agents. The minimum inhibitory concentrations of the SNPs that showed potential antibacterial action ranged from 8 to 128 µg/mL. Periodontal pathogens were used to perform qualitative evaluations of microbial adhesion and bacterial penetration through guided tissue regeneration membranes. The findings suggested that the presence of the SNPs could aid in the suppression of membrane-associated infection. Furthermore, when the anti-inflammatory action of the SNPs was tested using nitric oxide radical scavenging capacity and protein denaturation inhibition, it was discovered that the SNPs were extremely efficient at scavenging nitric oxide free radicals and had a strong anti-denaturation impact. The SNPs were found to be more cytotoxic to CAL27 than to human peripheral blood mononuclear cells (PBMCs), with IC50 values of 81.16 µg/mL in PBMCs and 34.03 µg/mL in CAL27. This study’s findings open a new avenue for using marine actinobacteria for silver nanoparticle biosynthesis, which holds great promise for a variety of biomedical applications, in particular periodontal treatment.

Biosynthesis of Zinc Nanoparticles From Actinobacterium Streptomyces Species and Their Biological Potential

“…Silver NPs synthesized from Actinobacteria obtained from the marine ecosystem were proven to be effective in periodontitis. On testing, it proved to suppress infection, reduce inflammation, anti-denaturation effect, and high cytotoxicity [ 24 ]. A microtiter-dilution resazurin test was used to assess the antibacterial efficacy of NP alone and in conjunction with antibiotics against multidrug-resistant (MDR) bacteria.…”

“…A microtiter-dilution resazurin test was used to assess the antibacterial efficacy of NP alone and in conjunction with antibiotics against multidrug-resistant (MDR) bacteria. It was found to have a synergistic effect [ 24 , 25 ]. ZnONPs have remarkable and incredible properties.…”

Exploring the potential of Rhizopus oryzae AUMC14899 as a novel endophytic fungus for the production of l-tyrosine and its biomedical applications

“…Most isolated bacteria from burn patients frequently develop biofilms on the ulcerated sections of burn wounds [ 4 ]. Microorganisms have created a variety of strategies to counter antimicrobial drugs, such as reducing cellular permeability to decrease drug penetration, enzymatically breaking down antimicrobial compounds, and forming biofilms [ 14 , 15 ].…”

“…Worldwide, MDR bacteria cause serious infections as a result of bacterial adaptation that includes the development of mutations, transformation, conjugation, transposition, and transduction [ 21 ]. Increasing MDR has generated scientific interest to discover novel antimicrobial agents with broad spectrum activities to complement and/or replace conventional antibiotics [ 5 , 15 , 22 ].…”

Statistical Medium Optimization for the Production of Anti-Methicillin-Resistant Staphylococcus aureus Metabolites from a Coal-Mining-Soil-Derived Streptomyces rochei CMB47

“…Significant examples are the polyketide antibiotics lankacidin and lankamycin from S. rochei 7434AN4 [10,11], the new metabolites from the coculture of the marine-derived actinobacterium Streptomyces rochei MB037 and the fungus Rinocladiella similis 35 [12]. Furthermore, it was reported that the marine-derived S. rochei MHM13 and S. rochei MS-37 have the ability to synthesize silver nanoparticles, exhibiting a wide range of inhibition against both Gram-positive and -negative bacteria [13,14]. Additionally, enzymes with biotechnological interest [15,16] are produced by a new soil-derived Streptomyces rochei subsp.…”